Blog

Moderna Price Levels to Watch After Stock’s 12% Surge on Tuesday Moderna (MRNA) experienced a significant uptick on Tuesday, with shares surging 12% to close at $47.53. This surge comes amid investor optimism regarding the pharmaceutical company’s development of a vaccine for the H5N1 bird flu, especially following the first reported death linked to the…

Stryker Acquires Inari Medical in $4.9 Billion Deal In a significant move to expand its medical device portfolio, Stryker Corporation (SYK.N) has announced its acquisition of Inari Medical (NARI.O) for an all-cash deal worth $4.9 billion. This acquisition is aimed at enhancing Stryker’s capabilities in treating venous diseases, particularly venous thromboembolism (VTE) and other vascular…

Why Walgreens Is Shuttering 1,200 Stores While Pharma Sales Soar To $722 Billion Walgreens is making a major strategic shift, announcing plans to close 1,200 stores in the next three years. This decision, though staggering in scale, reflects broader challenges within the pharmacy industry despite its significant size, which is projected to generate $722 billion…

Merck Enters Growing Obesity Drug Market with $2 Billion Deal In a significant move within the expanding market for obesity medications, Merck & Co. has secured a potential drug through a nearly $2 billion deal with Chinese drugmaker Hansoh Pharmaceutical Group Co. This acquisition allows Merck exclusive global rights to develop, manufacture, and commercialize the…

Healthcare Stocks Had a Dismal Year: Opportunities Ahead The healthcare sector has experienced a challenging year, with drug companies, health insurers, and hospital operators taking center stage in negative headlines. As political turbulence ramped up following President-elect Donald Trump’s nominees for the government’s public-health bureaucracy, popular discontent towards the healthcare system came to the forefront….

CVS Faces Historic Stock Decline Amid Bipartisan Criticism CVS Health Corp. is experiencing one of the worst months in its history, with its stock price headed towards a twelve-year closing low. Recent bipartisan criticisms from both the right and the left have left CVS and other pharmacy-benefit managers (PBMs) under significant scrutiny, raising questions about…

Novo’s New Deal May End Wegovy Shortages: A Potential Shift in the Pharmaceutical Industry The pharmaceutical landscape stands on the brink of transformation as Novo Nordisk announces plans to acquire key manufacturing sites poised to alleviate existing supply shortages of its popular obesity drug, Wegovy. This move not only aims to secure a stable supply…

The Weight-Loss Drug Market Is Heading for a Reckoning This Week This week marks a pivotal moment for the weight-loss drug industry, as the Food and Drug Administration (FDA) is expected to announce whether Eli Lilly’s obesity drug, Zepbound, can meet U.S. demand. The decision, set to be revealed on Thursday, could have far-reaching implications…

RFK Jr. Could Prove a Surprise Boon for Stem-Cell Stocks with Pivotal Year Ahead Insights from Maxim Group on Stem-Cell Stocks Stem-cell research is approaching a groundbreaking moment, with significant advancements anticipated as early as 2025. According to a recent report by Maxim Group, two biotech companies—Mesoblast Ltd. (MESO) and Capricor Therapeutics Inc. (CAPR)—are positioning…

Ro Partners with Eli Lilly to Enhance Access to Zepbound Vials Introduction to Eli Lilly’s Zepbound Eli Lilly (LLY) is taking significant steps in expanding access to its highly acclaimed weight loss medication, Zepbound, through a new partnership with telehealth platform Ro. The collaboration enables Ro to offer single-dose vials of Zepbound, which has emerged…